tiprankstipranks
Trending News
More News >

Pharma Mar’s Zepzelca® Shows Promising Results in Lung Cancer Treatment

Story Highlights
  • Pharma Mar SA develops innovative cancer drugs, focusing on marine-derived therapies.
  • Zepzelca® combined with atezolizumab improves survival in advanced-stage SCLC treatment.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Pharma Mar’s Zepzelca® Shows Promising Results in Lung Cancer Treatment

Don’t Miss TipRanks’ Half-Year Sale

Pharma Mar SA ( (ES:PHM) ) has shared an update.

Pharma Mar SA announced positive results from the phase 3 IMforte study, showcasing the effectiveness of Zepzelca® (lurbinectedin) combined with atezolizumab as a first-line maintenance treatment for advanced-stage small cell lung cancer (SCLC). The study demonstrated significant improvements in progression-free and overall survival, marking a potential new standard in SCLC treatment. The results were presented at the ASCO meeting and published in The Lancet, with a marketing authorization application submitted to the European Medicines Agency.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

More about Pharma Mar SA

Pharma Mar SA is a biopharmaceutical company focused on oncology, developing innovative drugs for cancer treatment. The company specializes in marine-derived drugs and has a significant presence in the global oncology market.

Average Trading Volume: 58,388

Technical Sentiment Signal: Strong Buy

Current Market Cap: €1.59B

See more data about PHM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1